Dr. Yazdani finished his undergraduate training at New York University and continued on to earn a medical degree at the same institution. His postgraduate training included a residency in internal medicine at Columbia Presbyterian Hospital followed by a Cardiology residency at the same institution. He then moved downtown to finish his interventional training at Mount Sinai Hospital. He finished his training in 1998 after which he joined a private practice in Easton, Pennsylvania. He moved to Northern Virginia in 2000 to be close to his family. He is one of the cofounders of Carient Heart and Vascular. Dr. Yazdani has always been a trailblazer in the field of interventional cardiology. He was the first operator in Northern Virginia to change to radial approach across the disease spectrum while performing cardiac interventions. He also started the first CTO program in the area. Chronic total occlusions (CTO) interventions involve opening arteries that have been closed more than 3 months. It is harder to open these arteries since they are not amenable to conventional interventional techniques. Dr Yazdani has applied new techniques to open these arteries and has helped many patients who otherwise were living with life limiting symptoms for many years. He has done more CTO procedures than any other interventional cardiologist in Northern Virginia. He has over two decades of experience in treating complex coronary lesions utilizing atherectomy, thrombectomy, hemodynamic support among other techniques.
Dr. Yazdani became interested in treating structural heart disease in 2012 as it became apparent that aortic valve disease, specifically aortic stenosis can be treat by transcatheter techniques instead of open heart surgery. He was involved in the initial trials looking at transcatheter therapy in patients at high or prohibitive risk for surgical valve replacement. Since then, he has been the primary investigator in many other trials including Partner 3, Early TAVR, Galileo among others. He has been the lead physician in bringing non-surgical alternative access such as Transcaval to Northern Virginia for patients who do not have good femoral access for their valve delivery. Dr. Yazdani has performed more TAVR procedures in Northern Virginia than any other operator.
Dr. Yazdani has been a pioneer in the area of non invasive treatment of mitral valve disease. He performed the first tran-septal mitral valve replacement in native mitral valve in the area a few years ago. At the time, only a few operators had performed this procedure nationwide. Since then, he has been instrumental in bringing different mitral valve treatment modalities such as Lampoon ( Laceration of the anterior leaflet of the mitral valve prior to transcatheter replacement of the Mitral valve ) to the area. He is the primary investigator for the Apollo trials that involves transcatheter replacement of mitral valve in patients at high or intermediate risk for surgical valve replacement. He is also performing catheter based mitral therapies such as MitraClip.
Dr. Yazdani is also involved in therapies geared toward patients with atrial fibrillation who are at high risk for taking blood thinners such as Coumadin. He performs implantation of left atrial appendage occluders such as Watchman regularly. Despite having a busy interventional practice, he also holds regular office hours in multiple locations in Northern Virginia including Vienna, Manassas and Warrenton.
Dr. Yazdani is recognized by Castle Connelly to be an American Top Doctor.